AngioDynamics, Inc., a healthcare company, recently announced that the FDA has approved their AlphaVac F1885 System for treating pulmonary embolism. This added approval allows the system to be more widely used in pulmonary embolism treatments, offering an increased number of alternatives for the patients affected by this condition. The company stated that this endorsement would help lower the thrombus burden in patients while enhancing the functionality of the right ventricle.
Presently, the AlphaVac F1885 System, a primary emergency medical device, is approved for eliminating thromboemboli, which are blood clots that have become dislodged and traveled to the lungs, from the venous system and for treating pulmonary embolism.
For additional health-related news, please visit rttnews.com.
